Clinics (Sao Paulo, Brazil) · 2025
Differential characteristics and outcomes of women and men undergoing Impella-supported high-risk PCI: IMPELLA-PL registry.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gąsecka Aleksandra, Pietrasik Arkadiusz, Sacha Jerzy, Pawłowski Tomasz, Grygier Marek, Łomiak Michał, Błażejowska Ewelina, Bartuś Stanisław, Rzeszutko Łukasz, Pawlik Artur, Kleczyński Pawel, Legutko Jacek, Kochman Janusz
Аннотация
BACKGROUND: Impella (Abiomed, Danvers, MA, USA) is a mechanical circulatory support device to prevent haemodynamic compromise in selected patients undergoing high-risk percutaneous coronary interventions.
OBJECTIVES: Data on sex differences in the setting of Impella-assisted high-risk percutaneous coronary interventions are limited. This analysis compared the characteristics and outcomes of women and men supported with Impella CP during high-risk percutaneous coronary interventions.
METHODS: Consecutive patients enrolled in the IMPELLA-PL registry, undergoing high-risk percutaneous coronary interventions from January 2014 until December 2021, with 12-month follow-up until December 2022, were included in the analysis. The main endpoints included (i) In-hospital mortality, (ii) Periprocedural complications, (iii) 12-month mortality, and major adverse cardiovascular events following hospital discharge.
RESULTS: Among 253 patients analyzed, women (12.6 %) were older (75.2 ± 7.7 years vs. 70.1 ± 10.0, p = 0.006), had more left main disease (81.2 % vs. 61.1 %, p = 0.043), and higher Syntax Score (46.0 vs. 42.5, p = 0.038). The in-hospital mortality rate was comparable between groups (9.4 % vs. 8.1 %, p = 0.736). Women experienced fewer device-related complications (6.3 % vs. 20.8 %, p = 0.049), but more systemic complications (68.8 % vs. 35.7 %, p < 0.001). Women trended towards lower 12-month mortality (9.4 % vs. 19.4 %, p = 0.053), while post-discharge major adverse cardiovascular events (15.6 % vs. 23.5 %, p = 0.439) were comparable.
CONCLUSIONS: Women and men undergoing Impella-assisted high-risk percutaneous coronary interventions have comparable in-hospital mortality rates, but different complication profiles. Following hospital discharge, the 12-month survival rate appears to be higher in women, despite more advanced age and a greater complexity of coronary artery disease.
OBJECTIVES: Data on sex differences in the setting of Impella-assisted high-risk percutaneous coronary interventions are limited. This analysis compared the characteristics and outcomes of women and men supported with Impella CP during high-risk percutaneous coronary interventions.
METHODS: Consecutive patients enrolled in the IMPELLA-PL registry, undergoing high-risk percutaneous coronary interventions from January 2014 until December 2021, with 12-month follow-up until December 2022, were included in the analysis. The main endpoints included (i) In-hospital mortality, (ii) Periprocedural complications, (iii) 12-month mortality, and major adverse cardiovascular events following hospital discharge.
RESULTS: Among 253 patients analyzed, women (12.6 %) were older (75.2 ± 7.7 years vs. 70.1 ± 10.0, p = 0.006), had more left main disease (81.2 % vs. 61.1 %, p = 0.043), and higher Syntax Score (46.0 vs. 42.5, p = 0.038). The in-hospital mortality rate was comparable between groups (9.4 % vs. 8.1 %, p = 0.736). Women experienced fewer device-related complications (6.3 % vs. 20.8 %, p = 0.049), but more systemic complications (68.8 % vs. 35.7 %, p < 0.001). Women trended towards lower 12-month mortality (9.4 % vs. 19.4 %, p = 0.053), while post-discharge major adverse cardiovascular events (15.6 % vs. 23.5 %, p = 0.439) were comparable.
CONCLUSIONS: Women and men undergoing Impella-assisted high-risk percutaneous coronary interventions have comparable in-hospital mortality rates, but different complication profiles. Following hospital discharge, the 12-month survival rate appears to be higher in women, despite more advanced age and a greater complexity of coronary artery disease.